|Bid||5.20 x 1000|
|Ask||5.35 x 1000|
|Day's Range||5.35 - 5.37|
|52 Week Range||4.83 - 7.00|
|Beta (3Y Monthly)||-0.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 11, 2019 - Nov 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.25|
Cumberland (CPIX) delivered earnings and revenue surprises of 42.86% and -8.01%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
NASHVILLE, Tenn. , Aug. 14, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company focused on hospital acute care and gastroenterology today announced ...
Cumberland (NASDAQ: CPIX ) releases its next round of earnings this Wednesday, August 14. Here's Benzinga's essential guide to Cumberland's Q2 earnings report. Earnings and Revenue Wall Street analysts ...
NASHVILLE, Tenn. , Aug. 7, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2019 financial results after the market closes on Wednesday, ...
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Solving superbugs remains an open question in the world of biotech. So why aren’t Bay Area drug companies and investors interested?
Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX): Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company...
Acer Therapeutics Inc. (ACER) receives a Complete Response Letter from the FDA regarding its new drug application for Edsivo for the treatment of vascular Ehlers-Danlos syndrome.
In the latest trading session, Cumberland Pharmaceuticals (CPIX) closed at $6.35, marking a +0.79% move from the previous day.
Taro Pharmaceutical (TARO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Cumberland Pharmaceuticals (CPIX) closed the most recent trading day at $6.19, moving -0.16% from the previous trading session.
“If we can bring the right people and the right brains and build out the infrastructure, we think we can build the industry,” Harrow Health CEO Mark Baum said.
A publicly traded health care company is relocating from the West Coast to Nashville — but it won’t be the typical Middle Tennessee health care firm.
The Zacks Analyst Blog Highlights: Flexible Solutions International, Qiwi, Cumberland Pharmaceuticals, CECO Environmental and Entravision Communications
Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
NASHVILLE, Tenn., May 15, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company, today announced it has entered into an exclusive agreement with China's Winhealth Pharma Group for the licensing rights of Acetadote® (acetylcysteine) Injection, used to prevent or reduce liver damage resulting from acetaminophen overdose, and Caldolor® (ibuprofen) Injection, which is used to treat pain and fever in the hospital setting. The agreement will provide Winhealth licensing rights to commercialize both FDA approved drugs in China, the second largest market for pharmaceuticals in the world after the U.S. There have been patents issued for both brands in China.
Cumberland (CPIX) delivered earnings and revenue surprises of 200.00% and 11.24%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?